PPD (PPD +0.9%) expands its laboratory test portfolio by adding five new molecular, serology and functional assays designed for COVID-19 vaccine and therapy development programs.
These assays have been developed to run on multiple assay platforms and are compatible with high-throughput liquid handling, in order to support large numbers of specimens.
The company also has developed a plate-based functional assay to detect anti-spike antibodies, by inhibiting binding of angiotensin converting enzyme 2 (ACE2) to SARS-CoV-2 spike protein, and prevent infection.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.